News

Droplet IV Aps (“Droplet IV”), a Danish medical device company developing a unique and proprietary automatic IV line flushing device, today announced a strengthening of its leadership team to accelerate its go-to-market efforts ahead of its first product launch in 2026. Henriette Kirkegaard has been appointed Chairperson of the Board, and Marcus Bech has been promoted to Chief Executive Officer (CEO). This leadership transition is part of Droplet IV’s ongoing efforts to prepare for the introduction of its first product and drive the company's growth in the coming years.

Leadership change to support market acceleration
As Droplet IV moves into 2025, co-founders and majority shareholders Tore Allerup and Marcus Bech have taken the decision to strengthen the company’s leadership structure. In addition to appointing Henriette Kirkegaard as Chairperson of the Board, Marcus Bech assumes the role of CEO, focusing on overseeing the company’s day-to-day operations.

Henriette Kirkegaard joins as Chairperson of the Board
Henriette Kirkegaard is an accomplished leader in the life science sector, with a track record of guiding companies through critical stages of growth and development. She is the former Co-founder and CEO of 3Dintegrated, which was sold to the world’s largest life sciences company in 2019. Over the past year, Henriette has worked closely with Droplet IV’s management team as a mentor and strategic advisor. “I’m excited to join Droplet IV as Chairperson of the Board,” said Henriette Kirkegaard. “I’ve been closely involved with the company over the past 12 months and am impressed by what Tore, Marcus, and the team have accomplished. Together, we will work to accelerate Droplet IV’s path to market and ensure the company is well-positioned to transform patient care in the IV space.”

Marcus Bech appointed CEO
Marcus Bech, co-founder and former co-CEO of Droplet IV, will now assume the role of CEO full-time, focusing on leading the company through its final regulatory and clinical stages toward product launch. Marcus has been instrumental in driving Droplet IV’s vision and strategy since its inception.

“I am honored to take on the role of CEO at this pivotal moment for Droplet IV,” said Marcus Bech. “Tore and I have worked together to optimize the company’s strategy, and with Henriette’s strategic oversight, I look forward to leading the team as we prepare for the introduction of our first product in 2026. Our vision of improving patient outcomes and reducing manual tasks for nurses is something we are all incredibly passionate about, and I’m eager to continue our progress toward market entry.”

Tore Allerup transitions to board role
Tore Allerup, co-founder of Droplet IV, will step down from his role as co-CEO and take a seat on the company’s Board of Directors. Tore will continue to provide strategic support to Marcus Bech and Henriette Kirkegaard as Droplet IV prepares for its next phase of growth.

“Marcus and I have worked together closely to develop a strategy that accelerates our time to market for our first product introduction,” said Tore Allerup. “With Henriette on board, I am confident that Droplet IV now have the leadership it needs to succeed. I look forward to supporting Marcus and the team in a strategic capacity as we prepare for market entry.”

About Droplet IV
Droplet IV, founded in 2022 and based in Copenhagen, Denmark, is a medical device company focused on developing a safe, simple, and cost-effective automatic IV line flushing solution. The company’s vision is to improve patient outcomes, reduce the time nurses spend on manual IV tasks, and eliminate unnecessary medical waste. The IV market is a $12Bn annual market and our objective is to introduce our first product to market in 2026 and scale our business in the following years.